Financhill
Sell
37

MBOT Quote, Financials, Valuation and Earnings

Last price:
$1.98
Seasonality move :
16.3%
Day range:
$1.95 - $2.06
52-week range:
$1.25 - $4.67
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.70x
Volume:
1.5M
Avg. volume:
1.3M
1-year change:
3.66%
Market cap:
$133M
Revenue:
--
EPS (TTM):
-$0.45

Analysts' Opinion

  • Consensus Rating
    Microbot Medical, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
  • Price Target Upside
    According to analysts' consensus price target of $8.75, Microbot Medical, Inc. has an estimated upside of 341.92% from its current price of $1.98.
  • Price Target Downside
    According to analysts, the lowest downside price target is $5.50 representing 100% downside risk from its current price of $1.98.

Fair Value

  • According to the consensus of 2 analysts, Microbot Medical, Inc. has 341.92% upside to fair value with a price target of $8.75 per share.

MBOT vs. S&P 500

  • Over the past 5 trading days, Microbot Medical, Inc. has underperformed the S&P 500 by -4.93% suggesting its relative strength compared to the major market average is weak at this time.

Share Buyback

  • Microbot Medical, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Microbot Medical, Inc. revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Microbot Medical, Inc. reported revenues of --.

Earnings Growth

  • Microbot Medical, Inc. has grown year-over-year earnings for 12 quarters straight. In the most recent quarter Microbot Medical, Inc. reported earnings per share of -$0.07.
Enterprise value:
53.7M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-4.87x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$63K
Return On Assets:
-41.62%
Net Income Margin (TTM):
--
Return On Equity:
-45.11%
Return On Invested Capital:
-44.68%
Operating Margin:
--
Trailing 12 Months Fiscal Quarters
Period Ending 2023-09-30 2024-09-30 2025-09-30 2024-09-30 2025-09-30
Income Statement
Revenue -- -- -- -- --
Gross Profit -$104K -$100K -$63K -$23K -$10K
Operating Income -$10.9M -$10.3M -$14M -$3.3M -$3.9M
EBITDA -$10.8M -$10.2M -$14M -$3.3M -$3.9M
Diluted EPS -$1.20 -$0.80 -$0.45 -$0.20 -$0.07
Period Ending 2021-09-30 2022-09-30 2023-09-30 2024-09-30 2025-09-30
Balance Sheet
Current Assets $18.8M $6.6M $8.4M $5M $80.8M
Total Assets $19.7M $7.4M $8.9M $5.2M $81.8M
Current Liabilities $1.4M $1.7M $1.5M $1.4M $2.9M
Total Liabilities $1.8M $1.9M $1.5M $1.4M $3.5M
Total Equity $17.9M $5.5M $7.4M $3.8M $78.2M
Total Debt $703K $226K $39K $29K $602K
Trailing 12 Months Fiscal Quarters
Period Ending 2023-09-30 2024-09-30 2025-09-30 2024-09-30 2025-09-30
Cash Flow Statement
Cash Flow Operations -$9.2M -$9M -$11M -$2.8M -$3.8M
Cash From Investing -$4.7M $3M -$69.4M $140K -$44.7M
Cash From Financing $10.9M $5.1M $86.6M $633K $51.2M
Free Cash Flow -$9.2M -$9M -$11M -$2.8M -$3.9M
MBOT
Sector
Market Cap
$133M
$25.9M
Price % of 52-Week High
42.4%
51.6%
Dividend Yield
0%
0%
Shareholder Yield
-43.19%
-1.66%
1-Year Price Total Return
3.67%
-18.99%
Beta (5-Year)
1.231
0.485
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

Technicals

8-day SMA
Sell
Level $2.08
200-day SMA
Sell
Level $2.61
Bollinger Bands (100)
Sell
Level 1.96 - 3.2
Chaikin Money Flow
Sell
Level -646.7K
20-day SMA
Sell
Level $2.10
Relative Strength Index (RSI14)
Sell
Level 40.20
ADX Line
Sell
Level 7.14
Williams %R
Buy
Level -88.6792
50-day SMA
Sell
Level $2.14
MACD (12, 26)
Buy
Level 0.16
25-day Aroon Oscillator
Sell
Level -24
On Balance Volume
Sell
Level -1.5M

Financial Scores

Sell
Altman Z-Score (Annual)
Level (-21.5912)
Sell
CA Score (Annual)
Level (-7.4933)
--
Beneish M-Score (Annual)
Level (--)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (13.5159)
--
Piotroski F Score (Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (2)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Microbot Medical, Inc. is a pre-clinical medical device company engaged in the research, design, development, and commercialization of micro-robotics assisted medical technologies. The firm carries out its operations through the ViRob and TipCat platforms. The ViRob platform technology is an autonomous crawling micro-robot that can be controlled remotely or within the body. It makes use of the Self-Cleaning Shunt, a robotic system designed as the ventricular catheter portion of a Cerebrospinal Fluid shunt system and is mainly used for the treatment of hydrocephalus and Normal Pressure Hydrocephalus. The TipCat platform, a self-propelling, flexible, and semi-disposable endoscope, provides see-and-treat capabilities within tubular lumens in the human body such as the colon, blood vessels, and the urinary tract. The company was founded by Harel Gadot, Moshe Shoham, and Yosseph Bornstein on August 2, 1988 and is headquartered in Hingham, MA.

Stock Forecast FAQ

In the current month, MBOT has received 2 Buy ratings 0 Hold ratings, and 0 Sell ratings. The MBOT average analyst price target in the past 3 months is $8.75.

  • Where Will Microbot Medical, Inc. Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Microbot Medical, Inc. share price will rise to $8.75 per share over the next 12 months.

  • What Do Analysts Say About Microbot Medical, Inc.?

    Analysts are divided on their view about Microbot Medical, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Microbot Medical, Inc. is a Sell and believe this share price will drop from its current level to $5.50.

  • What Is Microbot Medical, Inc.'s Price Target?

    The price target for Microbot Medical, Inc. over the next 1-year time period is forecast to be $8.75 according to 2 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.

  • Is MBOT A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Microbot Medical, Inc. is a Buy. 2 of 2 analysts rate the stock a Buy at this time.

  • How Can I Buy Shares Of MBOT?

    You can purchase shares of Microbot Medical, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Microbot Medical, Inc. shares.

  • What Is The Microbot Medical, Inc. Share Price Today?

    Microbot Medical, Inc. was last trading at $1.98 per share. This represents the most recent stock quote for Microbot Medical, Inc.. Yesterday, Microbot Medical, Inc. closed at $1.98 per share.

  • How To Buy Microbot Medical, Inc. Stock Online?

    In order to purchase Microbot Medical, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Palantir Stock Going to Crash?
Is Palantir Stock Going to Crash?

AI and data analytics major Palantir (NASDAQ:PLTR) has become something…

Why Did AMD Stock Go Up?
Why Did AMD Stock Go Up?

Since January 9th, shares of chipmaker AMD (NASDAQ:AMD) have been…

Will Data Centers Be In Space?
Will Data Centers Be In Space?

With demand for data centers seemingly growing by the day,…

Stock Ideas

Buy
59
Is NVDA Stock a Buy?

Market Cap: $4.6T
P/E Ratio: 64x

Buy
57
Is GOOG Stock a Buy?

Market Cap: $4T
P/E Ratio: 41x

Sell
47
Is GOOGL Stock a Buy?

Market Cap: $4T
P/E Ratio: 41x

Alerts

Buy
56
INTC alert for Jan 24

Intel Corp. [INTC] is down 17.01% over the past day.

Buy
64
BNR alert for Jan 24

Burning Rock Biotech Ltd. [BNR] is down 12.81% over the past day.

Sell
19
APGE alert for Jan 24

Apogee Therapeutics, Inc. [APGE] is down 12.28% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock